China Pharma Holdings (CPHI) Total Non-Current Liabilities (2010 - 2023)

China Pharma Holdings (CPHI) has reported Total Non-Current Liabilities for 11 consecutive years, with $10.5 million the latest figure, recorded in Q1 2023.

• For the quarter ending Q1 2023, Total Non-Current Liabilities changed N/A year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2023 stood at $10.5 million (changed N/A YoY), and the FY2022 full-year result was $11.1 million, down 24.71% from the prior year.
• Total Non-Current Liabilities retreated to $10.5 million in Q1 2023 per CPHI's latest filing, from $11.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $14.7 million in Q4 2021 and bottomed at $9.6 million in Q3 2021.
• Historically, Total Non-Current Liabilities has averaged $11.0 million across 5 years, with a median of $10.5 million in 2023.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities surged 42.28% in 2021, then dropped 24.71% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $10.6 million in 2019, then declined by 2.18% to $10.4 million in 2020, then soared by 42.28% to $14.7 million in 2021, then decreased by 24.71% to $11.1 million in 2022, then retreated by 5.3% to $10.5 million in 2023.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $10.5 million, $11.1 million, and $14.7 million for Q1 2023, Q4 2022, and Q4 2021 respectively.